Recent News

• 09.20.2026 - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
• 09.20.2026 - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
• 08.14.2026 - Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• 08.03.2026 - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
• 08.03.2026 - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
• 07.13.2026 - Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
• 07.10.2026 - Cue Biopharma Announces $50.0 Million Private Placement
• 06.10.2026 - Daniel Baker, M.D.
• 06.10.2026 - Daniel Baker, M.D.
• 06.10.2026 - Sumita Ray, J.D.

Recent Filings

• 09.21.2026 - 8-K Current report
• 09.21.2026 - EX-99.1 EX-99.1
• 08.28.2026 - 4/A Statement of changes in beneficial ownership of securities
• 08.28.2026 - 4/A Statement of changes in beneficial ownership of securities
• 08.21.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 08.20.2026 - EFFECT Notice of Effectiveness
• 08.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - 144 Report of proposed sale of securities